QC
BIO icon

Quadrature Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Quadrature Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07M Buy
+7,053
New +$2M 0.02% 494
2025
Q2 		– Sell
-1,064
Closed -$259K – 1056
2025
Q1 		$259K Sell
1,064
-736
-41% -$221K 0.01% 781
2024
Q4 		$592K Sell
1,800
-4,234
-70% -$1.44M 0.01% 545
2024
Q3 		$2.02M Buy
6,034
+739
+14% +$235K 0.05% 250
2024
Q2 		$1.45M Sell
5,295
-3,349
-39% -$974K 0.02% 374
2024
Q1 		$2.99M Sell
8,644
-15,176
-64% -$4.99M 0.05% 228
2023
Q4 		$7.7M Buy
23,820
+11,135
+88% +$3.49M 0.14% 104
2023
Q3 		$4.55M Buy
12,685
+12,143
+2,240% +$4.69M 0.09% 158
2023
Q2 		$205K Buy
542
+13
+2% +$5.29K ﹤0.01% 823
2023
Q1 		$254K Sell
529
-25,946
-98% -$12.1M 0.01% 711
2022
Q4 		$11.1M Buy
26,475
+16,654
+170% +$6.72M 0.33% 69
2022
Q3 		$4.1M Buy
9,821
+3,923
+67% +$1.96M 0.13% 161
2022
Q2 		$2.92M Sell
5,898
-9,893
-63% -$5.15M 0.12% 175
2022
Q1 		$8.89M Buy
15,791
+13,166
+502% +$7.94M 0.36% 69
2021
Q4 		$1.98M Buy
+2,625
New +$1.96M 0.1% 149
2021
Q3 		– Sell
-2,767
Closed -$1.78M – 707
2021
Q2 		$1.78M Buy
2,767
+700
+34% +$426K 0.07% 207
2021
Q1 		$1.18M Buy
+2,067
New +$1.22M 0.06% 280
2020
Q4 		– Sell
-1,600
Closed -$825K – 830
2020
Q3 		$825K Buy
+1,600
New +$810K 0.05% 390
2018
Q3 		– Sell
-1,528
Closed -$441K – 585
2018
Q2 		$441K Buy
+1,528
New +$422K 0.04% 337
2018
Q1 		– Sell
-3,124
Closed -$746K – 600
2017
Q4 		$746K Buy
+3,124
New +$757K 0.07% 266

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Quadrature Capital's BIO Position: Q2 2026 in Review

Quadrature Capital opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 7,053 shares worth $2.07M. The stake represents 0.02% of the portfolio and ranks #494 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in BIO as recently as Q1 2025.

Quadrature Capital first reported a position in BIO in Q4 2017 and has held it in 20 quarters since. The position peaked at $11.1M in Q4 2022. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Quadrature Capital held 7,053 shares of Bio-Rad Laboratories Class A worth $2.07M as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Quadrature Capital position in Q2 2026.
  • Bio-Rad Laboratories Class A made up 0.02% of Quadrature Capital's portfolio in Q2 2026, its #494 holding.
  • Quadrature Capital first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and has held it in 20 quarters since.
  • Quadrature Capital's Bio-Rad Laboratories Class A position peaked at $11.1M in Q4 2022.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.